All Updates

All Updates

icon
Filter
Partnerships
Tempus and AstraZeneca collaborate on NSCLC trial for biomarker discovery
Precision Medicine
Jul 13, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Jul 13, 2023

Tempus and AstraZeneca collaborate on NSCLC trial for biomarker discovery

Partnerships

  • AI-driven bioinformatics company Tempus has partnered with UK pharma giant AstraZeneca to conduct a trial on non-small cell lung cancer (NSCLC) aimed at creating a comprehensive dataset for biomarker discovery and precision medicine development.

  • The partnership involves enrolling two cohorts of NSCLC patients in the GEMINI trial. Tempus will utilize its sequencing assays to analyze the molecular profile of patients with stage IV NSCLC and early-stage disease eligible for surgery. The study will track patients for up to three years to understand tumor biology changes during disease progression and treatment. 

  • The findings could lead to the identification of new biomarkers, including circulating tumor DNA for measuring minimal residual disease (MRD). Tempus will leverage its multimodal data library and clinical trial matching program to enhance the study's reach and representativeness across the US patient population.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.